{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,8]],"date-time":"2026-10-08T04:57:23Z","timestamp":1791435443296,"version":"4.3.3"},"reference-count":50,"publisher":"BMJ","issue":"1","license":[{"start":{"date-parts":[[2026,1,30]],"date-time":"2026-01-30T00:00:00Z","timestamp":1769731200000},"content-version":"unspecified","delay-in-days":29,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"name":"1440 Foundation","award":["N\/A"],"award-info":[{"award-number":["N\/A"]}]},{"DOI":"10.13039\/100014547","name":"Parker Institute for Cancer Immunotherapy","doi-asserted-by":"publisher","award":["N\/A"],"award-info":[{"award-number":["N\/A"]}],"id":[{"id":"10.13039\/100014547","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000884","name":"Cancer Research Institute","doi-asserted-by":"publisher","award":["N\/A"],"award-info":[{"award-number":["N\/A"]}],"id":[{"id":"10.13039\/100000884","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Bristol Myers Squibb","award":["N\/A"],"award-info":[{"award-number":["N\/A"]}]}],"content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["J Immunother Cancer"],"accepted":{"date-parts":[[2026,1,12]]},"published-print":{"date-parts":[[2026,1]]},"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Patients with metastatic pancreatic ductal adenocarcinoma (mPDAC) often respond to cytotoxic therapy, but early disease progression is typical. Responses to immunotherapy alone are rare. Recent advances in chemoimmunotherapy combinations offer promise. We report results from cohorts A and B of REVOLUTION, an adaptive platform trial designed to evaluate the safety and antitumor activity of chemoimmunotherapy combinations in untreated mPDAC.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>\n                      REVOLUTION (\n                      <jats:ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" ext-link-type=\"clintrialgov\" xlink:href=\"NCT04787991\">NCT04787991<\/jats:ext-link>\n                      ) is an open-label, exploratory platform trial. Patients were assigned to enrolling cohorts in a non-randomized fashion. All patients received gemcitabine (1,000 mg\/m\n                      <jats:sup>2<\/jats:sup>\n                      ), nab-paclitaxel (125 mg\/m\n                      <jats:sup>2<\/jats:sup>\n                      ), and two doses of ipilimumab (1 mg\/kg), administered intravenously. In addition, cohort A received nivolumab (360 mg intravenously every 3 weeks) and cohort B received hydroxychloroquine (600 mg orally two times a day). The primary endpoint was safety. Secondary endpoints included objective response rate (ORR), disease control rate, duration of response, progression-free survival, and overall survival (OS). Exploratory endpoints included pharmacodynamic changes and associations between biomarkers and clinical outcomes.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      Both cohorts enrolled 15 patients. Grade 3\u20134 treatment-related adverse events occurred in 60% and 53% of patients in cohorts A and B, respectively. One grade 5 event occurred in cohort B, which exhibited more frequent dose modifications and non-compliance. Cohort A demonstrated an ORR of 33% (5\/15) and a 12-month OS rate of 65.5% (95% CI 35.7% to 84.0%), with higher baseline levels of programmed cell death protein-1 (PD-1)\n                      <jats:sup>+<\/jats:sup>\n                      CD39\n                      <jats:sup>+<\/jats:sup>\n                      central memory CD4\n                      <jats:sup>+<\/jats:sup>\n                      T cells associated with prolonged survival. Cohort B demonstrated an ORR of 40% (6\/15) and a 12-month OS rate of 53.9% (95% CI 24.3% to 76.3%). Cohort A showed increases in activated and proliferating CD4\n                      <jats:sup>+<\/jats:sup>\n                      and CD8\n                      <jats:sup>+<\/jats:sup>\n                      T cells, regulatory T cells, and circulating soluble PD-1 and Th1-associated cytokines. Cohort B exhibited delayed but sustained increases in activated CD4\n                      <jats:sup>+<\/jats:sup>\n                      T cells and pharmacodynamic evidence of autophagy inhibition.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>REVOLUTION cohorts A and B demonstrated encouraging antitumor activity in patients with mPDAC. In cohort B, hydroxychloroquine-related tolerability issues contributed to early discontinuations and reduced drug exposure. These findings highlight the potential and limitations of current chemoimmunotherapy approaches. Although neither cohort will be expanded, the results reinforce the continued promise of chemoimmunotherapy in mPDAC and the importance of refining these strategies.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1136\/jitc-2025-012864","type":"journal-article","created":{"date-parts":[[2026,1,30]],"date-time":"2026-01-30T11:35:24Z","timestamp":1769772924000},"page":"e012864","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":6,"title":["Clinical and translational results from a phase 1 trial of gemcitabine\/nab-paclitaxel with nivolumab\/ipilimumab or hydroxychloroquine\/ipilimumab in untreated metastatic pancreatic adenocarcinoma"],"prefix":"10.1136","volume":"14","clinical-trial-number":[{"clinical-trial-number":"nct04787991","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct04787991","registry":"10.18810\/clinical-trials-gov"}],"author":[{"given":"Eileen M","family":"O\u2019Reilly","sequence":"first","affiliation":[{"name":"Memorial Sloan Kettering Cancer Center, New York, New York, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0007-9938-1331","authenticated-orcid":false,"given":"Christopher R","family":"Cabanski","sequence":"additional","affiliation":[{"name":"Parker Institute for Cancer Immunotherapy, San Francisco, California, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jaclyn P","family":"Lyman","sequence":"additional","affiliation":[{"name":"Parker Institute for Cancer Immunotherapy, San Francisco, California, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zev A","family":"Wainberg","sequence":"additional","affiliation":[{"name":"University of California Los Angeles, Los Angeles, California, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"George A","family":"Fisher","sequence":"additional","affiliation":[{"name":"Department of Medicine, Stanford University School of Medicine, Stanford, California, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert A","family":"Wolff","sequence":"additional","affiliation":[{"name":"MD Anderson Gastrointestinal Cancer Center, Houston, Texas, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew H","family":"Ko","sequence":"additional","affiliation":[{"name":"Medicine (Division of Hematology\/Oncology), University of California San Francisco, San Francisco, California, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2751-6122","authenticated-orcid":false,"given":"Mark H","family":"O\u2019Hara","sequence":"additional","affiliation":[{"name":"Medicine, Hematology and Oncology, University of Pennsylvania, Philadelphia, Pennsylvania, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christine N","family":"Spencer","sequence":"additional","affiliation":[{"name":"Parker Institute for Cancer Immunotherapy, San Francisco, California, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jia Xin","family":"Yu","sequence":"additional","affiliation":[{"name":"Parker Institute for Cancer Immunotherapy, San Francisco, California, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7317-4886","authenticated-orcid":false,"given":"Diane M","family":"Da Silva","sequence":"additional","affiliation":[{"name":"Parker Institute for Cancer Immunotherapy, San Francisco, California, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lacey J","family":"Padr\u00f3n","sequence":"additional","affiliation":[{"name":"Parker Institute for Cancer Immunotherapy, San Francisco, California, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jamie","family":"Arnott","sequence":"additional","affiliation":[{"name":"Parker Institute for Cancer Immunotherapy, San Francisco, California, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Justin","family":"Fairchild","sequence":"additional","affiliation":[{"name":"Parker Institute for Cancer Immunotherapy, San Francisco, California, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jonni S","family":"Moore","sequence":"additional","affiliation":[{"name":"Abramson Cancer Center, Philadelphia, Pennsylvania, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brandon","family":"Peng","sequence":"additional","affiliation":[{"name":"University of Pennsylvania, Philadelphia, Pennsylvania, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"William A","family":"Hoos","sequence":"additional","affiliation":[{"name":"1440 Foundation, Scotts Valley, California, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jill","family":"O\u2019Donnell-Tormey","sequence":"additional","affiliation":[{"name":"Cancer Research Institute, New York, New York, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Silvia","family":"Boffo","sequence":"additional","affiliation":[{"name":"Bristol Myers Squibb, Princeton, New Jersey, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ute","family":"Dugan","sequence":"additional","affiliation":[{"name":"Parker Institute for Cancer Immunotherapy, San Francisco, California, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alec C","family":"Kimmelman","sequence":"additional","affiliation":[{"name":"NYU Langone Health Perlmutter Cancer Center, New York, New York, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ravi K","family":"Amaravadi","sequence":"additional","affiliation":[{"name":"University of Pennsylvania, Philadelphia, Pennsylvania, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert H","family":"Vonderheide","sequence":"additional","affiliation":[{"name":"Abramson Cancer Center, Philadelphia, Pennsylvania, USA"},{"name":"Parker Institute for Cancer Immunotherapy, Philadelphia, Pennsylvania, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"239","published-online":{"date-parts":[[2026,1,30]]},"reference":[{"key":"2026013003351492000_14.1.e012864.1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.20.01364"},{"key":"2026013003351492000_14.1.e012864.2","doi-asserted-by":"publisher","DOI":"10.3322\/caac.21871"},{"key":"2026013003351492000_14.1.e012864.3","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1011923"},{"key":"2026013003351492000_14.1.e012864.4","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1304369"},{"key":"2026013003351492000_14.1.e012864.5","doi-asserted-by":"crossref","first-page":"418","DOI":"10.1016\/j.trecan.2018.04.001","article-title":"Immunotherapy and Prevention of Pancreatic Cancer","volume":"4","author":"Morrison","year":"2018","journal-title":"Trends Cancer"},{"key":"2026013003351492000_14.1.e012864.6","doi-asserted-by":"crossref","first-page":"1431","DOI":"10.1001\/jamaoncol.2019.1588","article-title":"Durvalumab With or Without Tremelimumab for Patients With Metastatic Pancreatic Ductal Adenocarcinoma: A Phase 2 Randomized Clinical Trial","volume":"5","author":"O\u2019Reilly","year":"2019","journal-title":"JAMA Oncol"},{"key":"2026013003351492000_14.1.e012864.7","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-022-01829-9"},{"key":"2026013003351492000_14.1.e012864.8","doi-asserted-by":"crossref","DOI":"10.3390\/jcm13216419","article-title":"Updates in Immunotherapy for Pancreatic Cancer","volume":"13","author":"Chick","year":"2024","journal-title":"J Clin Med"},{"key":"2026013003351492000_14.1.e012864.9","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2024.1383978","article-title":"Frontiers and future of immunotherapy for pancreatic cancer: from molecular mechanisms to clinical application","volume":"15","author":"Zheng","year":"2024","journal-title":"Front Immunol"},{"key":"2026013003351492000_14.1.e012864.10","doi-asserted-by":"publisher","DOI":"10.1126\/science.aan6733"},{"key":"2026013003351492000_14.1.e012864.11","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(20)30445-9"},{"key":"2026013003351492000_14.1.e012864.12","doi-asserted-by":"publisher","DOI":"10.1158\/2326-6066.CIR-14-0215"},{"key":"2026013003351492000_14.1.e012864.13","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-20-0099"},{"key":"2026013003351492000_14.1.e012864.14","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-022-32591-8"},{"key":"2026013003351492000_14.1.e012864.15","doi-asserted-by":"publisher","DOI":"10.1101\/gad.287524.116"},{"key":"2026013003351492000_14.1.e012864.16","doi-asserted-by":"publisher","DOI":"10.1016\/j.cmet.2017.04.004"},{"key":"2026013003351492000_14.1.e012864.17","doi-asserted-by":"crossref","first-page":"617","DOI":"10.3389\/fonc.2018.00617","article-title":"Metabolic Dependencies in Pancreatic Cancer","volume":"8","author":"Vaziri-Gohar","year":"2018","journal-title":"Front Oncol"},{"key":"2026013003351492000_14.1.e012864.18","doi-asserted-by":"publisher","DOI":"10.1101\/gad.2016111"},{"key":"2026013003351492000_14.1.e012864.19","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-11-1094"},{"key":"2026013003351492000_14.1.e012864.20","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.1703921114"},{"key":"2026013003351492000_14.1.e012864.21","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1038\/s41586-020-2229-5","article-title":"Autophagy promotes immune evasion of pancreatic cancer by degrading MHC-I","volume":"581","author":"Yamamoto","year":"2020","journal-title":"Nature New Biol"},{"key":"2026013003351492000_14.1.e012864.22","doi-asserted-by":"crossref","first-page":"4214","DOI":"10.1158\/0008-5472.CAN-24-0830","article-title":"Combined Autophagy Inhibition and Dendritic Cell Recruitment Induces Antitumor Immunity and Enhances Immune Checkpoint Blockade Sensitivity in Pancreatic Cancer","volume":"84","author":"Oyama","year":"2024","journal-title":"Cancer Res"},{"key":"2026013003351492000_14.1.e012864.23","doi-asserted-by":"crossref","first-page":"993","DOI":"10.1001\/jamaoncol.2019.0684","article-title":"Effect of Gemcitabine and nab-Paclitaxel With or Without Hydroxychloroquine on Patients With Advanced Pancreatic Cancer: A Phase 2 Randomized Clinical Trial","volume":"5","author":"Karasic","year":"2019","journal-title":"JAMA Oncol"},{"key":"2026013003351492000_14.1.e012864.24","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-19-4042"},{"key":"2026013003351492000_14.1.e012864.25","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(16)30624-6"},{"key":"2026013003351492000_14.1.e012864.26","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1910231"},{"key":"2026013003351492000_14.1.e012864.27","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(20)30641-0"},{"key":"2026013003351492000_14.1.e012864.28","doi-asserted-by":"publisher","DOI":"10.1016\/0197-2456(89)90015-9"},{"key":"2026013003351492000_14.1.e012864.29","unstructured":"Parker institute for cancer immunotherapy. data from: clinical and translational results from a phase 1 trial of gemcitabine\/nab-paclitaxel with nivolumab\/ipilimumab or hydroxychloroquine\/ipilimumab in untreated metastatic pancreatic adenocarcinoma. GitHub; 2025. Available: https:\/\/github.com\/ParkerICI\/revolution-trial-data"},{"key":"2026013003351492000_14.1.e012864.30","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0095192","article-title":"Homogenous 96-plex PEA immunoassay exhibiting high sensitivity, specificity, and excellent scalability","volume":"9","author":"Assarsson","year":"2014","journal-title":"PLoS One"},{"key":"2026013003351492000_14.1.e012864.31","doi-asserted-by":"crossref","DOI":"10.1084\/jem.20240152","article-title":"Immunologic signatures of response and resistance to nivolumab with ipilimumab in advanced metastatic cancer","volume":"221","author":"Tsimberidou","year":"2024","journal-title":"J Exp Med"},{"key":"2026013003351492000_14.1.e012864.32","doi-asserted-by":"crossref","DOI":"10.1186\/s13073-015-0197-4","article-title":"Achieving high-sensitivity for clinical applications using augmented exome sequencing","volume":"7","author":"Patwardhan","year":"2015","journal-title":"Genome Med"},{"key":"2026013003351492000_14.1.e012864.33","doi-asserted-by":"publisher","DOI":"10.1101\/gr.107524.110"},{"key":"2026013003351492000_14.1.e012864.34","doi-asserted-by":"publisher","DOI":"10.1038\/ng.806"},{"key":"2026013003351492000_14.1.e012864.35","doi-asserted-by":"publisher","DOI":"10.4161\/auto.29119"},{"key":"2026013003351492000_14.1.e012864.36","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.0806075105"},{"key":"2026013003351492000_14.1.e012864.37","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-10-0505"},{"key":"2026013003351492000_14.1.e012864.38","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1158\/2326-6066.CIR-13-0020","article-title":"Increased frequency of ICOS+ CD4 T cells as a pharmacodynamic biomarker for anti-CTLA-4 therapy [published correction appears in Cancer Immunol Res","volume":"1","author":"Ng Tang","year":"2014","journal-title":"Cancer Immunol Res"},{"key":"2026013003351492000_14.1.e012864.39","doi-asserted-by":"crossref","DOI":"10.1186\/s12885-018-4584-2","article-title":"Chloroquine reduces hypercoagulability in pancreatic cancer through inhibition of neutrophil extracellular traps","volume":"18","author":"Boone","year":"2018","journal-title":"BMC Cancer"},{"key":"2026013003351492000_14.1.e012864.40","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1093\/cei\/uxad005","article-title":"Chloroquine reduces neutrophil extracellular trap (NET) formation through inhibition of peptidyl arginine deiminase 4 (PAD4)","volume":"211","author":"Ivey","year":"2023","journal-title":"Clin Exp Immunol"},{"key":"2026013003351492000_14.1.e012864.41","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1186\/s12950-025-00456-8","article-title":"Hydroxychloroquine reduces metastatic tumor burden in pancreatic adenocarcinoma through myeloperoxidase inhibition","volume":"22","author":"Niemann","year":"2025","journal-title":"J Inflamm (Lond)"},{"key":"2026013003351492000_14.1.e012864.42","doi-asserted-by":"publisher","DOI":"10.1038\/cgt.2015.21"},{"key":"2026013003351492000_14.1.e012864.43","doi-asserted-by":"publisher","DOI":"10.1245\/s10434-018-6941-4"},{"key":"2026013003351492000_14.1.e012864.44","doi-asserted-by":"publisher","DOI":"10.1016\/j.smim.2021.101481"},{"key":"2026013003351492000_14.1.e012864.45","doi-asserted-by":"crossref","DOI":"10.3390\/cancers13205086","article-title":"TGF\u03b2 Signaling in the Pancreatic Tumor Microenvironment","volume":"13","author":"Principe","year":"2021","journal-title":"Cancers (Basel)"},{"key":"2026013003351492000_14.1.e012864.46","doi-asserted-by":"crossref","DOI":"10.3390\/cancers16030559","article-title":"The Role of Chemokines in Orchestrating the Immune Response to Pancreatic Ductal Adenocarcinoma","volume":"16","author":"Lekan","year":"2024","journal-title":"Cancers (Basel)"},{"key":"2026013003351492000_14.1.e012864.47","doi-asserted-by":"publisher","DOI":"10.1016\/j.immuni.2019.09.013"},{"key":"2026013003351492000_14.1.e012864.48","doi-asserted-by":"crossref","DOI":"10.3389\/fcell.2021.640224","article-title":"Eomes Impedes Durable Response to Tumor Immunotherapy by Inhibiting Stemness, Tissue Residency, and Promoting the Dysfunctional State of Intratumoral CD8+ T Cells","volume":"9","author":"Sun","year":"2021","journal-title":"Front Cell Dev Biol"},{"key":"2026013003351492000_14.1.e012864.49","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0287738","article-title":"Hydroxychloroquine reduces T cells activation recall antigen responses","volume":"18","author":"Kowatsch","year":"2023","journal-title":"PLoS One"},{"key":"2026013003351492000_14.1.e012864.50","doi-asserted-by":"publisher","DOI":"10.1245\/s10434-015-4566-4"}],"container-title":["Journal for ImmunoTherapy of Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/jitc-2025-012864","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,30]],"date-time":"2026-01-30T11:35:27Z","timestamp":1769772927000},"score":1,"resource":{"primary":{"URL":"https:\/\/jitc.bmj.com\/lookup\/doi\/10.1136\/jitc-2025-012864"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1]]},"references-count":50,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,1,30]]},"published-print":{"date-parts":[[2026,1]]}},"alternative-id":["10.1136\/jitc-2025-012864"],"URL":"https:\/\/doi.org\/10.1136\/jitc-2025-012864","relation":{},"ISSN":["2051-1426"],"issn-type":[{"value":"2051-1426","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,1]]}}}